about
A testing procedure for survival data with few responders.Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data.Strength of accumulating evidence and data monitoring committee decision making.Preliminary data release for randomized clinical trials of noninferiority: a new proposal.Release of data from an ongoing randomized clinical trial for sample size adjustment or planning.Randomized clinical trials with biomarkers: design issues.Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.Robust genomic control for association studies.Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007Two-stage adaptive cutoff design for building and validating a prognostic biomarker signatureOutcome--adaptive randomization: is it useful?Assessing treatment benefit with competing risks not affected by the randomized treatment.Overall survival as the outcome for randomized clinical trials with effective subsequent therapiesTargeting epidermal growth factor receptor--are we missing the mark?An audit strategy for progression-free survival.Design issues in randomized phase II/III trials.Testing treatment effects in the presence of competing risks.Randomized phase II trial designs with biomarkers.NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.Proposal for the use of progression-free survival in unblinded randomized trials.Design Issues in Randomized Clinical Trials of Maintenance Therapies.Monitoring for lack of benefit: a critical component of a randomized clinical trialPhase III clinical trials that integrate treatment and biomarker evaluationBlinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005.Multi-arm clinical trials of new agents: some design considerations.Statistical and practical considerations for clinical evaluation of predictive biomarkers.Statistical challenges in the evaluation of treatments for small patient populations.An audit strategy for time-to-event outcomes measured with error: application to five randomized controlled trials in oncology.Marker Sequential Test (MaST) design.New challenges for comparative effectiveness in oncology: choice of primary end points for randomized clinical trials.Biomarker enrichment strategies: matching trial design to biomarker credentials.Sample size adjustment designs with time-to-event outcomes: A caution.Comparison of futility monitoring guidelines using completed phase III oncology trials.Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.Information time scales for interim analyses of randomized clinical trials.Design issues of randomized phase II trials and a proposal for phase II screening trials.RE: Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval.A model too far.Efficiency robust tests for mapping quantitative trait loci using extremely discordant sib pairs.
P50
Q30669468-BC06643B-757E-46BB-8C67-44CC27E18423Q30746030-1E2C26C2-88AB-4C26-9360-4C48047BD383Q30952565-10892232-1D5F-4936-8429-BB58A176B170Q30995017-6CE7EB26-B107-4C43-A97C-DB47E309488CQ33275980-75A72682-9FAD-4703-BF8B-077D4AC82205Q34024227-E9FDEA66-BC1D-432F-8823-19A04707C4F1Q34149992-3E5933E2-B6DC-4D9F-B2EA-4CFA2632C21AQ34398890-498DE01A-6B27-4C76-BDB4-213736FF7EB1Q34488684-5EB336F7-D512-4FA7-9646-66C2C7785939Q34490312-2DAA6BC5-59D8-45A0-AFEE-2B8EF2A96752Q34667846-5B94CE86-5F89-4214-8BC5-125A4B982821Q34716955-628093FB-A82D-45A4-88A2-CEEA07B7F354Q35023481-70077C34-27E2-4CF7-B919-2D1B461BAB97Q35174501-757E5540-C4E3-493D-8D9C-CDBCD52E404CQ35177892-C1988A11-43DD-425F-9304-A6836D55ABBDQ35808427-61C5972E-C5B1-4EA5-8D79-AD1DEC147A9CQ36038605-F6DC590C-C957-4851-BBE7-239C1D2E4179Q36212448-396D3862-D5CE-4F41-828E-8E254DC9BEA9Q36507559-2AF1744E-A286-4D2C-9144-15B3C07F156BQ36826988-0B348989-6DCB-48A8-97E2-3DBF494A5EFBQ36848078-CFC8A813-B8D8-40E7-B0E7-05D1ABD3516EQ37104771-FDBCE4F4-3772-49A7-8433-5D41DDA83A2AQ37122311-B50CD506-4BDA-4FAD-8386-554A0958E980Q37126131-12572268-C9D6-406A-A886-5A6EBCDA66D2Q37158281-57E2E884-5C3B-43AA-B439-E7032D47F647Q37217136-C8C7557F-D27F-4E2E-918F-C73F8949EE81Q37463622-715B77ED-09E6-46C8-BDBD-90676DC2A97DQ38093778-93C48B6F-8042-4821-AF7E-A2514B46317FQ38128282-8C8AE3F0-0C46-4BF5-B586-BF67B564F111Q38148514-33E3971E-8CC9-4D80-99F6-EFAA1A3E671EQ38162911-CD9FCC55-9074-4371-9A2A-1BF0CC806D63Q38166566-742528A8-9905-442F-8B46-420D4E340810Q38630899-F01F733C-1400-4435-AF05-1174C7CB4D15Q39427133-B9AD0E31-5BE7-483A-A75A-A4B072137159Q39772400-CE33DE98-517F-404E-93AA-BE9A0AFB9B62Q39802570-B3A92C29-FF19-48B0-AE45-429C4663B656Q40385205-1F6EA321-D1E5-44C3-BBDD-BE856C7E4354Q42381429-4BBCE399-D0CF-4566-B56F-52B6B60387B0Q42573803-5E239DF0-CB39-43A6-8398-3E232598E556Q42606618-32A2A287-29FF-4C01-BAB7-9691BF3C2105
P50
name
Boris Freidlin
@ast
Boris Freidlin
@en
Boris Freidlin
@nl
type
label
Boris Freidlin
@ast
Boris Freidlin
@en
Boris Freidlin
@nl
prefLabel
Boris Freidlin
@ast
Boris Freidlin
@en
Boris Freidlin
@nl